Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
South Korea
Biotech
With $30M, Oorja Bio breathes new life into fibrosis candidate
The biotech’s lead asset is ORJ-001, an activator of a receptor called β1 integrin that is key for maintaining lung structure and stability.
Darren Incorvaia
May 20, 2026 10:31am
Lilly pledges $500M to South Korea biopharma industry
Mar 10, 2026 12:00pm
Roche pumps $480M into South Korea biopharma industry
Mar 4, 2026 11:22am
Sanofi signs 2nd biotech deal of the day
Dec 15, 2025 5:50pm
Korean CRO inks collab to expand into organoids, transcriptomics
Jul 22, 2025 3:10pm
Radyus and Dt&CRO partner to bring South Korean biotechs to US
May 14, 2024 3:20pm
